BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 9556788)

  • 1. Status of antiestrogen breast cancer prevention trials.
    Powles TJ
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen-receptor modulators in 2001.
    O'Regan RM; Gradishar WJ
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tamoxifen and breast cancer: is everything known already?].
    Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
    Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of tamoxifen on the endometrium.
    Barakat RR
    Oncology (Williston Park); 1995 Feb; 9(2):129-34; discussion 139-40, 142. PubMed ID: 8771096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant trials of toremifene vs tamoxifen: the European experience.
    Holli K
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II and III clinical trials of toremifene for metastatic breast cancer.
    Vogel CL
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):9-13. PubMed ID: 9556785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-estrogens come of age: a pioneer looks back.
    Nelson NJ
    J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
    [No Abstract]   [Full Text] [Related]  

  • 8. Should you be taking tamoxifen?
    Johns Hopkins Med Lett Health After 50; 2001 Jun; 13(4):4-5. PubMed ID: 11439691
    [No Abstract]   [Full Text] [Related]  

  • 9. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
    Ziegler J
    J Natl Cancer Inst; 1996 Aug; 88(16):1100-2. PubMed ID: 8757185
    [No Abstract]   [Full Text] [Related]  

  • 11. Tamoxifen in cancer therapy: minireview.
    Novotny L; Rauko P; Vachálková A; Peterson-Biggs M
    Neoplasma; 2000; 47(1):3-7. PubMed ID: 10870680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a new prevention maintenance therapy for postmenopausal women.
    Jordan VC
    Recent Results Cancer Res; 1999; 151():96-109. PubMed ID: 10337721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of breast cancer.
    Prichard RS; Hill AD; Dijkstra B; McDermott EW; O'Higgins NJ
    Br J Surg; 2003 Jul; 90(7):772-83. PubMed ID: 12854100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
    Jordan VC
    Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen debate hinges on whose risk is high enough.
    Reynolds T
    J Natl Cancer Inst; 1998 Oct; 90(19):1428-30. PubMed ID: 9776407
    [No Abstract]   [Full Text] [Related]  

  • 18. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
    Mäenpää JU; Ala-Fossi SL
    Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen and the endometrium.
    Barakat RR
    Cancer Treat Res; 1998; 94():195-207. PubMed ID: 9587689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.